Early experimental results of using a novel delivery carrier, Hyaluronan-phosphatidylethanolamine (HA-PE) which may allow simple bladder instillation of Botulinum Toxin A as effectively as direct detrusor muscle injection.
- Publication Year:
- Usage 79
- Downloads 56
- Bepress 56
- Abstract Views 23
- Bepress 23
- Repository URL:
- https://ir.lib.uwo.ca/etd/4233; https://ir.lib.uwo.ca/cgi/viewcontent.cgi?article=5936&context=etd
- Botulinum Toxin A; Detrusor overactivity; modulated carrier; Bladder instillations; SNAP-25 cleavage; urodynamic assessment; Surgery; Urology
Intra-detrusor Botulinum Toxin-A (BTX-A) injection is the gold standard treatment for detrusor overactivity in clinical practice when medical treatment fails. Despite satisfactory results of BTX-A injection, the endoscopic procedure still has risks of anaesthetic and operative complications. Several studies have investigated more simple ways to deliver BTX-A to the detrusor muscle but with limited success. In our study, we assessed the evidence of BTX-A delivery using a newly modulated hyaluronan-phosphatidylethanolamine (HA-PE) carrier in a rat model through BTX-A-HA-PE bladder instillations. We used histological evidence of SNAP-25 protein cleavage and detection of Alexa FluorÒ594-labelled BTX-A as a proof of physical BTX-A delivery across the urothelium. In addition, we assessed the functional impact of using HA-PE on rat detrusor muscle through urodynamic assessment both at baseline and 2 weeks later after 1% acetic acid instillation. We found positive histological evidence of SNAP-25 cleavage, detection of Alexa FluorÒ594-BTX-A red fluorescence in bladder tissue supporting that HA-PE may be an efficient carrier to deliver BTX-A across the urothelium.